[
    {
        "pregunta": "1. What is the recommended pneumococcal vaccination strategy for patients with rheumatic and musculoskeletal diseases (RMD) under the age of 65 who are taking immunosuppressive medication?",
        "respuesta": "For patients with rheumatic and musculoskeletal diseases (RMD) under the age of 65 who are taking immunosuppressive medication, the pneumococcal vaccination is strongly recommended. This recommendation is based on the increased risk of pneumococcal infection for patients with RMDs who are on immunosuppressive medication.",
        "contexto": [
            "Pneumococcal vaccination For patients with RMD age <65 years who are taking immunosuppressive medication, pneumococcal vaccination is strongly recommended. Patients with RMDs taking immunosuppressive medication may be at increased risk of pneumococcal infection There are few studies evaluating the impact of diseasemodifying antirheumatic drugs (DMARDs) on conjugate pneumococcal vaccines. The ACIP recommends administering pneumococcal vaccination to individuals age >18 years with certain chronic",
            "| For patients with RMD age &lt;65 years who are taking immunosuppressive medication, pneumococcal vaccination is strongly recommended. |                                                  |                                                                                                                      |                          |",
            "Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal",
            "and not after booster The 2022 ACR guideline for vaccination in adults and children with RMDs highlights the following: 1) pneumococcal vaccination should be administered to all RMD patients taking immunosuppressive medication; 2) recombinant zoster vaccination is recommended for RMD patients >18 years of age taking immunosuppressive medication; 3) methotrexate should be held for 2 weeks after influenza vaccination if disease activity allows; 4) seasonal influenza vaccination should be",
            "RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended. For patients with RMD aged >18 years who are on immunosuppressive medication, administering the recombinant zoster vaccine is strongly recommended. For patients with RMD aged >26 and <45 years who are on immunosuppressive medication and not previously vaccinated, vaccination against HPV is conditionally recommended. Revised February 24, 2023 Whether to give multiple vaccinations to RMD"
        ]
    },
    {
        "pregunta": "2. Should patients with RMD receive vaccination against varicella-zoster virus (VZV) at age under 50 years if they are taking immunosuppressive medication?",
        "respuesta": "Yes, patients with rheumatic and musculoskeletal diseases (RMD) who are under the age of 50 and taking immunosuppressive medication should receive vaccination against varicella-zoster virus (VZV), as administering the recombinant VZV vaccine is strongly recommended for patients with RMD age >18 years who are on immunosuppressive medication.",
        "contexto": [
            "pneumococcal vaccination to individuals age >18 years with certain chronic medical conditions and those taking immunosuppressive medication Recombinant varicella-zoster virus (VZV) vaccination For patients with RMD age >18 years who are taking immunosuppressive medication, administering the recombinant VZV vaccine is strongly recommended. Patients with RMDs such as systemic lupus erythematosus (SLE) and RA are at higher risk of herpes zoster than older adults recommended for vaccination Human",
            "RMD aged <65 years who are on immunosuppressive medication, pneumococcal vaccination is strongly recommended. For patients with RMD aged >18 years who are on immunosuppressive medication, administering the recombinant zoster vaccine is strongly recommended. For patients with RMD aged >26 and <45 years who are on immunosuppressive medication and not previously vaccinated, vaccination against HPV is conditionally recommended. Revised February 24, 2023 Whether to give multiple vaccinations to RMD",
            "risk of herpes zoster than older adults recommended for vaccination Human papillomavirus (HPV) vaccination For patients with RMD age >26 years and <45 years who are taking immunosuppressive medication and not previously vaccinated, vaccination against HPV is conditionally recommended. Patients taking immunosuppressive medication may be at increased risk of cervical dysplasia and cervical cancer Whether to hold immunosuppressive medication at the time of non-live attenuated vaccination to",
            "Shared decision-making with patients is encouraged in clinical settings. Expanded indications for specific vaccines in patients with RMDs on immunosuppression For RMD patients aged ≥ 65 years, and RMD patients aged >18 and <65 years who are on immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is conditionally recommended over giving regular-dose influenza vaccination. For patients with RMD aged <65 years who are on immunosuppressive medication, pneumococcal",
            "| For patients with RMD age &gt;18 years who are taking immunosuppressive medication, administering the recombinant VZV vaccine is strongly recommended. |                                                  |                                                                                                                      |                          |"
        ]
    },
    {
        "pregunta": "3. What is the recommended approach for patients with RMD who are taking rituximab in terms of timing non-live attenuated vaccine administration relative to the next dose of medication?",
        "respuesta": "For patients with rheumatic and musculoskeletal diseases (RMD) who are taking rituximab, it is conditionally recommended to defer non-live attenuated vaccinations, with the exception of the influenza vaccination, until the next rituximab administration is due. Additionally, it is recommended to delay rituximab for 2 weeks after vaccination to maximize vaccine efficacy. This approach is based on the need to optimize immunization responses while managing the timing of rituximab treatments.",
        "contexto": [
            "| <strong>For patients with RMD receiving rituximab, deferring non–live attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison",
            "| <strong>Timing vaccinations in patients receiving rituximab to maximize vaccine efficacy</strong>    | <strong>Low</strong>                                          | PICO 17. Should patients with RMD who are taking rituximab time non–live attenuated vaccine administration relative to the next dose of medication? | 927–930                  |",
            "vaccination. Two RCTs performed in patients initiating TNFi versus placebo demonstrated similar responses to influenza vaccination in the 2 arms Rituximab For patients with RMD receiving rituximab, administering influenza vaccination on schedule is conditionally recommended rather than deferring vaccination until the next rituximab administration is due. For patients with RMD receiving rituximab, deferring non-live attenuated vaccinations, other than influenza vaccination, until the next",
            "if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology.",
            "attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended. Influenza vaccine responses are greater when the vaccine is administered later rather than earlier after rituximab Whether to administer non-live attenuated vaccinations to patients receiving glucocorticoids or with active disease (Table 4 Glucocorticoids Whether to administer non-live attenuated"
        ]
    },
    {
        "pregunta": "4. How does the immunogenicity or efficacy of influenza vaccine differ in patients with RMD taking high-dose steroids compared to those taking lower doses or not taking steroids?",
        "respuesta": "The provided information does not offer specific details on the difference in immunogenicity or efficacy of the influenza vaccine in patients with rheumatic and musculoskeletal diseases (RMD) who are taking high-dose steroids compared to those who are either taking lower doses or not taking steroids. The information available is noted as being of very low quality and does not provide clear comparative data or outcomes between these patient groups.",
        "contexto": [
            "|          |    PICO 14. Very low     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "| <strong>For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone &gt;10 mg daily but &lt;20 mg daily, administering any non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579",
            "| <strong>Whether to administer non–live attenuated vaccinations to patients receiving glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579",
            "regarding influenza vaccination, which is administered seasonally and is recommended for RMD patients even if their disease activity is high, they are taking high-dose glucocorticoids, and/or are taking rituximab. The Voting Panel generally favored simple recommendations to encourage vaccination and foster guideline adherence. There are few studies assessing the immunogenicity and safety of specific vaccines in relation to specific immunosuppressive medications, and there are virtually no"
        ]
    },
    {
        "pregunta": "5. Should patients with RMD taking the equivalent of prednisone ≤10 mg daily receive any non-live attenuated vaccinations?",
        "respuesta": "Yes, for patients with rheumatic and musculoskeletal diseases (RMD) who are taking the equivalent of prednisone ≤10 mg daily, administering any non-live attenuated vaccinations is strongly recommended.",
        "contexto": [
            "| For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non–live attenuated vaccinations is strongly recommended. |                                                  |                                                                                                                      |                          |",
            "disease (Table 4 Glucocorticoids Whether to administer non-live attenuated vaccinations to patients taking glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity. For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non-live vaccinations is strongly recommended. For patients with RMD who are taking the equivalent of prednisone >10 mg daily but <20 mg daily, administering any non-live attenuated vaccinations is",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone &gt;10 mg daily but &lt;20 mg daily, administering any non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579",
            "but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non–live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as"
        ]
    },
    {
        "pregunta": "6. What is the recommended vaccination approach for patients with RMD taking the equivalent of prednisone >10 mg daily but <20 mg daily in terms of non-live attenuated vaccinations?",
        "respuesta": "For patients with rheumatic and musculoskeletal diseases (RMD) who are taking the equivalent of prednisone >10 mg daily but <20 mg daily, the administration of any non-live attenuated vaccinations is conditionally recommended.",
        "contexto": [
            "| For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non–live attenuated vaccinations is strongly recommended. |                                                  |                                                                                                                      |                          |",
            "but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally",
            "disease (Table 4 Glucocorticoids Whether to administer non-live attenuated vaccinations to patients taking glucocorticoids or defer vaccination to a later time point to maximize vaccine immunogenicity. For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non-live vaccinations is strongly recommended. For patients with RMD who are taking the equivalent of prednisone >10 mg daily but <20 mg daily, administering any non-live attenuated vaccinations is",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone &gt;10 mg daily but &lt;20 mg daily, administering any non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579",
            "| <strong>For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non–live attenuated vaccinations, other than the influenza vaccine, until glucocorticoids are tapered to the equivalent of prednisone &lt;20 mg daily is conditionally recommended.</strong> | <strong>Low for pneumococcal vaccines, very low for other vaccines</strong> | PICO 4. In patients with RMD, does the immunogenicity or efficacy of vaccine Z differ in patients taking high‐dose steroids as"
        ]
    },
    {
        "pregunta": "7. Should patients with RMD taking the equivalent of prednisone ≥20 mg daily receive influenza vaccination?",
        "respuesta": "For patients with rheumatic and musculoskeletal diseases (RMD) who are taking the equivalent of prednisone ≥20 mg daily, administering the influenza vaccination is conditionally recommended.",
        "contexto": [
            "| <strong>For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended.</strong> | <strong>Very low</strong>                                     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "but <20 mg daily, administering any non-live attenuated vaccinations is conditionally recommended. For patients with RMD taking the equivalent of prednisone ≥20 mg daily, administering influenza vaccination is conditionally recommended. For patients with RMD who are taking the equivalent of prednisone ≥20 mg daily, deferring non-live attenuated vaccinations, other than influenza vaccination, until glucocorticoids are tapered to the equivalent of prednisone <20 mg daily is conditionally",
            "influenza, there are inactivated alternatives that can be safely given to RMD patients taking immunosuppressive medication. Conventional DMARDs. Two observational studies in patients with RMDs who were only taking conventional DMARDs and/or prednisone <20 mg daily at the time they received the yellow fever vaccine observed no cases of infection 68 Biologic DMARDs. In a large RCT of RMD patients taking TNFi who were given the live attenuated VZV vaccine, there were no confirmed cases of",
            "| For patients with RMD who are taking the equivalent of prednisone ≤10 mg daily, administering any non–live attenuated vaccinations is strongly recommended. |                                                  |                                                                                                                      |                          |",
            "if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology."
        ]
    },
    {
        "pregunta": "8. What is the effect of drug Y or drug class on immunization responses to vaccine Z in patients with RMD compared to the general population or another drug?",
        "respuesta": "The provided information indicates that there is very low to moderate quality evidence regarding the effect of drug Y or drug class on immunization responses to vaccine Z in patients with rheumatic and musculoskeletal diseases (RMD) in comparison to the general population or to patients taking another drug. Therefore, specific details about the comparative effect of drug Y or drug class on vaccine responses in RMD patients cannot be reliably stated based on the available data.",
        "contexto": [
            "| <strong>For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |",
            "| <strong>For patients with RMD, continuing immunosuppressive medications around the time of other (non‐influenza) non–live attenuated vaccinations is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550                    |",
            "| <strong>Whether to hold immunosuppressive medication at the time of non–live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison with [general population, or drug Y]? | 7–550",
            "| <strong>For patients with RMD receiving rituximab, deferring non–live attenuated vaccinations, other than influenza vaccination, until the next rituximab administration is due, and delaying rituximab for 2 weeks after vaccination, is conditionally recommended.</strong> | <strong>Very low for most comparisons, moderate for a few</strong> | PICO 3. In patients with [RMD disease X], what is the effect of [drug Y/drug class] on immunization responses to [vaccine Z, vaccine type] in comparison",
            "influenza vaccination, recombinant VZV vaccination, and primary and booster COVID-19 vaccination in RMD patients taking immunosuppressive medication; and 4) RCTs to test the safety and efficacy of holding DMARDs around the time of vaccination.  † The terms 'moderate', 'low', and 'very low' are based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) definitions for quality of evidence. Moderate quality means that \"further research is likely to have an important"
        ]
    },
    {
        "pregunta": "9. Should patients with RMD hold methotrexate for 2 weeks after influenza vaccination if disease activity allows?",
        "respuesta": "Yes, for patients with rheumatic and musculoskeletal diseases (RMD), holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming that disease activity allows.",
        "contexto": [
            "| For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. |                                                  |                                                                                                                      |                          |",
            "medication at the time of non-live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare (Table 3 Methotrexate For patients with RMD, holding methotrexate for 2 weeks after influenza vaccination is conditionally recommended, assuming disease activity allows. For patients with RMD, continuing immunosuppressive medications other than methotrexate around the time of influenza vaccination is conditionally recommended. For",
            "<p>*Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</p>\n\n<p>**Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>",
            "<ul>\n<li>Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient’s rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.</li>\n</ul>\n\n<p>† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.</p>",
            "if disease activity allows; 4) seasonal influenza vaccination should be administered to RMD patients even if their disease is active, they are taking high-dose glucocorticoids, and/or they are taking rituximab; 5) in RMD patients taking rituximab, vaccines other than for influenza should be administered at least 6 months after the last rituximab METHODS This guideline follows ACR policy guiding management of conflicts of interest and disclosures ( https://www.rheumatology."
        ]
    },
    {
        "pregunta": "10. Is there a difference in the seroconversion rates between younger patients with rheumatoid arthritis receiving high-dose influenza vaccination compared to standard-dose vaccination?",
        "respuesta": "Yes, based on the provided information, two randomized controlled trials (RCTs) in rheumatoid arthritis (RA) patients showed that younger patients receiving high-dose influenza vaccination had higher seroconversion rates compared to those receiving standard-dose vaccination. There was no safety signal observed, indicating that the high-dose vaccine was well-tolerated.",
        "contexto": [
            "restrictions may preclude administration of high-dose or adjuvanted influenza vaccination to patients <65 years of age. High-dose influenza vaccine is a quadrivalent vaccine containing 4 times the antigen as the standard-dose vaccine. Two RCTs in rheumatoid arthritis (RA) patients showed higher seroconversion rates in younger patients receiving high-dose vaccination compared to standard-dose vaccination with no safety signal Pneumococcal vaccination For patients with RMD age <65 years who are",
            "or efficacy of vaccine Z differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 551–579                  |",
            "|          |    PICO 14. Very low     | PICO 14. In patients with RMD, does the immunogenicity or efficacy of influenza vaccine differ in patients taking high‐dose steroids as compared to those taking lower doses of steroids or those not taking steroids? | 739–754                  |",
            "|                                                                                       |                                                  | PICO 11. In patients with RMD &lt;65 years of age, is high‐ dose vaccine more effective than seasonal regular‐dose influenza vaccine? | 728–737                  |",
            "| For patients with RMD age ≥65 years and patients with RMD age &gt;18 and &lt;65 years who are taking immunosuppressive medication, giving high‐dose or adjuvanted influenza vaccination is conditionally recommended over giving regular‐dose influenza vaccination. |                                                  | PICO 9. In patients with RMD age ≥65 years, is high‐dose influenza vaccine more effective than seasonal regular‐dose influenza vaccine? | 728                      |"
        ]
    }
]